[HTML][HTML] Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

…, M Sznol, DF McDermott, HM Kluger… - Journal of clinical …, 2014 - ncbi.nlm.nih.gov
Purpose Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T
cells that downmodulates effector functions and limits the generation of immune memory. PD-…

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

…, EC Holman, M Bosenberg, M Sznol, HM Kluger… - Nature …, 2012 - nature.com
We characterized the mutational landscape of melanoma, the form of skin cancer with the
highest mortality rate, by sequencing the exomes of 147 melanomas. Sun-exposed …

[HTML][HTML] PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma

…, SP Fling, PA Friedlander, HM Kluger… - … England Journal of …, 2016 - Mass Medical Soc
Background Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell …

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 …

…, H Gerrish, X Yao, V Chiang, HM Kluger - The lancet …, 2016 - thelancet.com
Background Immunotherapy targeting the PD-1 axis has activity in several tumour types. We
aimed to establish the activity and safety of the PD-1 inhibitor pembrolizumab in patients …

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 …

…, R Gupta, H Wyatt, M Ribeiro, Y Kluger… - The Lancet …, 2020 - thelancet.com
Background We did a phase 2 trial of pembrolizumab in patients with non-small-cell lung
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of PD-…

Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas

…, KR Williams, H Zhao, S Ariyan, A Lin, HM Kluger… - Cancer research, 2004 - AACR
Affymetrix and spotted oligonucleotide microarrays were used to assess global differential
gene expression comparing normal human melanocytes with six independent melanoma cell …

High HSP90 expression is associated with decreased survival in breast cancer

E Pick, Y Kluger, JM Giltnane, C Moeder, RL Camp… - Cancer research, 2007 - AACR
The heat shock protein HSP90 chaperones proteins implicated in breast cancer progression,
including Her2/neu. HSP90-targeting agents are in clinical trials for breast cancer. HSP90 …

KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements

…, LB Jilaveanu, W Damsky, M Sznol, HM Kluger… - Nature, 2021 - nature.com
Tumours use various strategies to evade immune surveillance 1 , 2 . Immunotherapies
targeting tumour immune evasion such as immune checkpoint blockade have shown …

[HTML][HTML] Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab

…, I Puzanov, FS Hodi, HM Kluger… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
Purpose Blockade of the programmed death-1 inhibitory cell-surface molecule on immune
cells using the fully human immunoglobulin G4 antibody nivolumab mediates tumor …

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

…, S Ariyan, D Narayan, M Sznol, HM Kluger… - Nature …, 2015 - nature.com
We report on whole-exome sequencing (WES) of 213 melanomas. Our analysis established
NF1, encoding a negative regulator of RAS, as the third most frequently mutated gene in …